Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Km Biologics Co. Ltd. manages 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This active case represents the entirety of the company's current engagement with the patent office in the life sciences sector. The presence of a pending action indicates a focused prosecution effort for the company's biological intellectual property.
This matter is assigned to 1 distinct examiner and a specific art unit. This concentration suggests that the company's technical developments are categorized within a very narrow specialized group. James Henry Alstrum Acevedo is the busiest examiner for the company, handling the pending office action. The alignment of all active work under this individual creates a centralized prosecution environment.
Practitioners should note that the results of the company's current patenting efforts are heavily influenced by the specific examination approach of James Henry Alstrum Acevedo. While this centralization simplifies the management of active cases, it also means the portfolio does not benefit from a diversity of examiner viewpoints. Future applications in the Biotechnology & Pharmaceuticals area are likely to remain within this art unit if they maintain similar technical claims.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ALSTRUM ACEVEDO, JAMES HENRY | 1 | 40.8% | -19.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18609457 | TISSUE FIBROSIS INHIBITOR IN WHICH BIOCOMPATIBLE POLYMER IS USED | ALSTRUM ACEVEDO, JAMES HENRY | 22d overdue |
| Art Unit | Apps |
|---|---|
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18609457 | TISSUE FIBROSIS INHIBITOR IN WHICH BIOCOMPATIBLE POLYMER IS USED | ALSTRUM ACEVEDO, JAMES HENRY | 1622 | §102§103Other | Non-Final OA | 22d overdue | Pending | Mar 19, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial